Pharmacotherapy for the prevention of post-ERCP pancreatitis

Erina Foster, Joseph Leung

Research output: Contribution to journalArticle

14 Scopus citations

Abstract

Post-ERCP pancreatitis (PEP) is a potential complication of ERCP. Pharmacotherapy for prevention of PEP aims at reducing basal sphincter pressure and contractility or a decrease in pancreatic secretion to reduce intraductal pressure. Timing and route of administration of drugs are critical to ensure maximum benefits from medications. Pancreatic stenting offers an alternative to decompress the pancreas and is effective in reducing PEP in high-risk patients.

Original languageEnglish (US)
Pages (from-to)52-55
Number of pages4
JournalAmerican Journal of Gastroenterology
Volume102
Issue number1
DOIs
StatePublished - Jan 2007

ASJC Scopus subject areas

  • Gastroenterology

Fingerprint Dive into the research topics of 'Pharmacotherapy for the prevention of post-ERCP pancreatitis'. Together they form a unique fingerprint.

  • Cite this